Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden

Robinson, David; Garmo, Hans; Lindahl, Bertil; Hemelrijck, Mieke Van; Adolfsson, Jan; Bratt, Ola; Holmberg, Lars; Stattin, Pär

doi:10.1002/ijc.26022

Cited by 21 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings also are consistent with autopsy study of Stamatiou suggesting that men with PCa had greater advanced atheromatosis than subjects without PCa [30]. A study of 30,883 men with PCa hormone-naive, showed a statistical significantly increase in risk of ischemic heart disease for all men with PCa versus controls [33]. Similarly, Zoller et al showed an increased risk of CAD during the first 6 months after diagnosis of PCa and after 10 years after diagnosis of cancer [34].…”

Section: Discussionsupporting

confidence: 91%

Obesity, Diabetes Mellitus and Vascular Disease: A Complex Relationship with Prostate Cancer

Francesco¹,

Tenaglia²

2014

JCT

View full text Add to dashboard Cite

Background: Obesity, type II Diabetes mellitus (DMII) and vascular damage could be implicated in prostate cancer (PCa) nevertheless no clear results has been reached. The aim of the research was to investigate the association of these alterations with PCa at initial diagnosis, without the influence of hormone therapy or chemotherapy. Methods: Retrospective analysis of 400 patients undergoing prostate biopsy at our institution between 2005 and 2012 was conducted. We examined associations of obesity, DMII and vascular damage in 200 patients with PCa diagnosis versus 200 age-matched controls. Men with history of hormone therapy or chemotherapy, prostate or bladder surgery were excluded. Results: Obesity was significantly associated (OR 2.10, p < 0.05) with aggressive PCa (Gleason Score 8 -10). DMII was significantly associated to aggressive PCa but only in obese cases (OR 4.25). Carotid vascular disease (CVD) and coronary artery disease (CAD) were significantly linked to PCa in all cases versus controls (OR 1.88, p < 0.05). Conclusions: In our study, obesity, particularly in combination with DMII, was significantly associated with aggressive PCa. Moreover, a significant relation was found between vascular disease and PCa hormone-naïve at initial diagnosis. The metabolic derangements associated to obesity and DMII may increase oxidative stress and cause a permanent pro-inflammatory state that predisposes to vascular disease and PCa.

show abstract

Section: Discussionsupporting

confidence: 91%

Obesity, Diabetes Mellitus and Vascular Disease: A Complex Relationship with Prostate Cancer

Francesco¹,

Tenaglia²

2014

JCT

View full text Add to dashboard Cite

show abstract

“…A recent Swedish population-based study demonstrated that, regardless of treatment, men with prostate cancer exhibited a small increase in stroke risk, compared with an age-matched control population. However, the initiation of endocrine treatment is not associated with an increased risk of stroke (25). A 5-year follow-up study in Taiwan presented a similar conclusion, showing no significant difference in stroke risk between ethnic Chinese patients with prostate cancer who did vs those who did not receive ADT (26).…”

Section: Discussionsupporting

confidence: 60%

Association of Intensive Morphine Treatment and Increased Stroke Incidence in Prostate Cancer Patients: A Population-based Nested Case–Control Study

Lee

Muo

Liang

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: We address the potential problem of stroke induced by morphine exposure by comparing the incidence of stroke in cancer patients treated with and without morphine. Methods: We performed a population-based nested case -control retrospective analysis on the Longitudinal Health Insurance Database 2000 and Registry for Catastrophic Illness Patients of Taiwan. This study is based on a malignancy cohort of 31 611 patients without a history of stroke, and 1208 patients who subsequently developed stroke served as the stroke group. Four controls of matched age, sex, entry year and entry month for each case were selected from the malignancy cohort from the non-stroke group. We used logistic regression to estimate the odds ratios and 95% confidence intervals, and applied the multivariable model to control for age, sex, hypertension, diabetes, hyperlipidemia and cardiovascular disease. Results: Cancer patients who received morphine had a 12% higher risk of developing stroke than non-morphine users. However, the difference was nonsignificant. A significant difference only appears in prostate cancer patients, where morphine users have a 3.02-fold (4.24-and 2.90-fold for hemorrhagic and ischemic strokes, respectively) higher risk of suffering from stroke. The risk increased significantly as the morphine dosage increased to 170 mg/year of treatment. Conclusions: Intense morphine treatment may be associated with an increased stroke incidence in patients with malignancy, and the association is particularly significant for prostate cancer patients.

show abstract

“…One [24] of these four studies [4], [13], [24], [25] using the same database were included because of more complete and recent data. Meanwhile, among another three studies [26]–[28] coming from the same database, Hemelrijck et al's [28] was included at last for the complete data. Two [29], [30] were excluded because the database were not population-based.…”

Section: Resultsmentioning

confidence: 99%

Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies

et al. 2014

View full text Add to dashboard Cite

BackgroundThere is no consensus regarding whether androgen deprivation therapy (ADT) is associated with cardiovascular disease (CVD) and cardiovascular mortality (CVM). The objective of this study was to determine the role of ADT for prostate cancer (PCa) in development of cardiovascular events (CVD and CVM).Methods and FindingsWe performed a meta-analysis from population-based observational studies comparing ADT vs control aimed at treating PCa in patients with PCa, reporting either CVD or CVM as outcome. Publications were searched using Medline, Embase, Cochrane Library Central Register of observational studies database up to May 31th 2014, and supplementary searches in publications from potentially relevant journals. 6 studies were identified with a total of 129,802 ADT users and 165,605 controls investigating the relationship between ADT and CVD. The incidence of CVD was 10% higher in ADT groups, although no significant association was observed (HR = 1.10, 95%CIs: 1.00–1.21; P = 0.06). For different types of ADT, CVD was related with gonadotropin-releasing hormone (GnRH) (HR = 1.19, 95%CIs: 1.04–1.36; P<0.001) and GnRH plus oral antiandrogen (AA) (HR = 1.46, 95%CIs: 1.03–2.08; P = 0.04), but not with AA alone or orchiectomy. For CVM, 119,625 ADT users and 150,974 controls from 6 eligible studies were included, pooled results suggested that ADT was associated with CVM (HR = 1.17, 95%CIs: 1.04–1.32; P = 0.01). Significantly increased CVM was also detected in GnRH and GnRH plus AA groups. When patients received other treatments (e.g. prostatectomy and radiotherapy) were ruled out of consideration, more increased CVD (HR = 1.19, 95%CIs: 1.08–1.30; P<0.001) and CVM (HR = 1.30, 95%CIs: 1.13–1.50; P<0.001) were found in men treated with ADT monotherapy.ConclusionsADT is associated with both CVD and CVM. Particularly, GnRH alone and GnRH plus AA can significantly increase the incidence of cardiovascular events in patients with PCa.

show abstract

Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden

Cited by 21 publications

References 22 publications

Obesity, Diabetes Mellitus and Vascular Disease: A Complex Relationship with Prostate Cancer

Obesity, Diabetes Mellitus and Vascular Disease: A Complex Relationship with Prostate Cancer

Association of Intensive Morphine Treatment and Increased Stroke Incidence in Prostate Cancer Patients: A Population-based Nested Case–Control Study

Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies

Contact Info

Product

Resources

About